He contributed to discovery of TGF-beta1 as a key regulator in subchondral bone disturbance and osteoarthritis pathogenesis (Nature Medicine 2013). His work has been recognized by Young Investigator Award, Mr. Savio Woo and Mrs. Pattie Woo Travel Fellowship, AOSpine East Asia (AOSEA) Research Grant award and AOSEA Travel Grant, and Oldendorf Award. Since joining PolyU BME, Dr. Wen’s research centers on vascular etiology of osteoarthritis. Under the auspices of RGC ECS and GRF, Dr. Wen and his team finally identified endothelin-1 (ET-1), the most potent vasoconstrictor in hypertension, contributing to articular chondrocyte senescence and osteoarthritis pathology (Osteoarthritis and Cartilage 2015 and 2020). It substantiates the vascular etiology hypothesis of osteoarthritis and opens a new avenue for discovery of novel mechanism-based disease-modifying therapies against osteoarthritis (Nature Review Rheumatology 2021) Along this research direction, Dr. Wen has secured the external research fund over 10 million HKD in the capacity of PI from RGC, HMRF and ITF. Meanwhile, we kicked off formal research collaboration with world-leading research institutes such as Kennedy Institute of Rheumatology, University of Oxford (Prof. Tonia Vincent, HMRF research fellowship) and Sorbonne University in Paris (Prof. Francis Berenbaum, PROCORE-France/Hong Kong Joint Research Scheme and INSERM International Research Program). Dr. Wen envisions developing PolyU BME as a regional leading and international renowned osteoarthritis research center.